178 related articles for article (PubMed ID: 37506141)
1. STK11 mutation impacts CD1E expression to regulate the differentiation of macrophages in lung adenocarcinoma.
Zhang Q; Feng J; Liu K; Yang X; Huang Y; Tang B
Immun Inflamm Dis; 2023 Jul; 11(7):e958. PubMed ID: 37506141
[TBL] [Abstract][Full Text] [Related]
2. STK11 mutation affects the killing effect of NK cells to promote the progression of lung adenocarcinoma.
Huang Y; Zhang H; Feng J; Tang B
APMIS; 2022 Nov; 130(11):647-656. PubMed ID: 35988018
[TBL] [Abstract][Full Text] [Related]
3. Exosomes from M1-polarized macrophages promote apoptosis in lung adenocarcinoma via the miR-181a-5p/ETS1/STK16 axis.
Wang X; Huang R; Lu Z; Wang Z; Chen X; Huang D
Cancer Sci; 2022 Mar; 113(3):986-1001. PubMed ID: 35092121
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of STK11 with different mutation status and its relationship with tumor-infiltrating immune cells in non-small cell lung cancer.
Zheng J; Deng Y; Huang B; Chen X
Front Immunol; 2024; 15():1387896. PubMed ID: 38736875
[TBL] [Abstract][Full Text] [Related]
5. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
[TBL] [Abstract][Full Text] [Related]
6. STK11 loss leads to YAP1-mediated transcriptional activation in human KRAS-driven lung adenocarcinoma cell lines.
Lenahan SM; Sarausky HM; Deming P; Seward DJ
Cancer Gene Ther; 2024 Jan; 31(1):1-8. PubMed ID: 37968341
[TBL] [Abstract][Full Text] [Related]
7. Emerging Therapeutic Implications of STK11 Mutation: Case Series.
Laderian B; Mundi P; Fojo T; E Bates S
Oncologist; 2020 Sep; 25(9):733-737. PubMed ID: 32396674
[TBL] [Abstract][Full Text] [Related]
8. Redox
Wei XW; Lu C; Zhang YC; Fan X; Xu CR; Chen ZH; Wang F; Yang XR; Deng JY; Yang MY; Gou Q; Mei SQ; Luo WC; Zhong RW; Zhong WZ; Yang JJ; Zhang XC; Tu HY; Wu YL; Zhou Q
Oncoimmunology; 2024; 13(1):2340154. PubMed ID: 38601319
[TBL] [Abstract][Full Text] [Related]
9. STK11 (LKB1) mutation suppresses ferroptosis in lung adenocarcinoma by facilitating monounsaturated fatty acid synthesis.
Zou Q; Tang B; Chen X; Zhang C; Huang Y
Open Med (Wars); 2024; 19(1):20230845. PubMed ID: 38205151
[TBL] [Abstract][Full Text] [Related]
10. Relevance of STK11 Mutations Regarding Immune Cell Infiltration, Drug Sensitivity, and Cellular Processes in Lung Adenocarcinoma.
Li Z; Ding B; Xu J; Mao K; Zhang P; Xue Q
Front Oncol; 2020; 10():580027. PubMed ID: 33425731
[TBL] [Abstract][Full Text] [Related]
11. A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.
Chen L; Engel BE; Welsh EA; Yoder SJ; Brantley SG; Chen DT; Beg AA; Cao C; Kaye FJ; Haura EB; Schabath MB; Cress WD
J Thorac Oncol; 2016 Jun; 11(6):838-49. PubMed ID: 26917230
[TBL] [Abstract][Full Text] [Related]
12. Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional
Pore N; Wu S; Standifer N; Jure-Kunkel M; de Los Reyes M; Shrestha Y; Halpin R; Rothstein R; Mulgrew K; Blackmore S; Martin P; Meekin J; Griffin M; Bisha I; Proia TA; Miragaia RJ; Herbst R; Gupta A; Abdullah SE; Raja R; Frigault MM; Barrett JC; Dennis PA; Ascierto ML; Oberst MD
Cancer Discov; 2021 Nov; 11(11):2828-2845. PubMed ID: 34230008
[TBL] [Abstract][Full Text] [Related]
13. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
Qian Y; Galan-Cobo A; Guijarro I; Dang M; Molkentine D; Poteete A; Zhang F; Wang Q; Wang J; Parra E; Panda A; Fang J; Skoulidis F; Wistuba II; Verma S; Merghoub T; Wolchok JD; Wong KK; DeBerardinis RJ; Minna JD; Vokes NI; Meador CB; Gainor JF; Wang L; Reuben A; Heymach JV
Cancer Cell; 2023 Jul; 41(7):1363-1380.e7. PubMed ID: 37327788
[TBL] [Abstract][Full Text] [Related]
14. ANGPT1 promotes M1 macrophage polarization and inhibits lung adenocarcinoma progression by inhibiting the TGF-β signalling pathway.
Liu G; Zhang H
Gen Physiol Biophys; 2024 Mar; 43(2):121-138. PubMed ID: 38477603
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma.
Gao Y; Päivinen P; Tripathi S; Domènech-Moreno E; Wong IPL; Vaahtomeri K; Nagaraj AS; Talwelkar SS; Foretz M; Verschuren EW; Viollet B; Yan Y; Mäkelä TP
Clin Cancer Res; 2022 Jan; 28(1):227-237. PubMed ID: 34667030
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
Rosellini P; Amintas S; Caumont C; Veillon R; Galland-Girodet S; Cuguillière A; Nguyen L; Domblides C; Gouverneur A; Merlio JP; Bezin J; Girodet PO
Eur J Cancer; 2022 Sep; 172():85-95. PubMed ID: 35759814
[TBL] [Abstract][Full Text] [Related]
17. Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation.
Wang H; Guo J; Shang X; Wang Z
Int Immunopharmacol; 2020 Jul; 84():106574. PubMed ID: 32413741
[TBL] [Abstract][Full Text] [Related]
18.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
19. Overexpression and Selective Anticancer Efficacy of
Park C; Lee Y; Je S; Chang S; Kim N; Jeong E; Yoon S
Mol Cells; 2019 Nov; 42(11):804-809. PubMed ID: 31697874
[TBL] [Abstract][Full Text] [Related]
20. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
Sun D; Qian H; Wang J; Xie T; Teng F; Li J; Xing P
Cell Commun Signal; 2022 Oct; 20(1):156. PubMed ID: 36229854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]